Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

187.51 +1.80 (+0.97%)
Official Closing Price Updated: 6:30 PM EDT, Aug 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,351,030
Open 187.90
Bid (Size) 186.90 (3)
Ask (Size) 187.47 (2)
Prev. Close 185.71
Today's Range 185.98 - 189.59
52wk Range 135.85 - 193.91
Shares Outstanding N/A
Dividend Yield 3.16%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Warren Buffett's Approach To Investing In Election Years
Warren Buffett, known as the 'Oracle of Omaha', is a highly successful American investor who manages his portfolio consistently, regardless of elections or market conditions. 
Via Benzinga
Elliott Wave Technical Analysis: AbbVie Inc.
An in-depth look at ABBV's price movements using the Elliott Wave Theory, helping traders identify potential opportunities based on current trends and market structure. 
Via Talk Markets

Performance

YTD
+17.33%
+17.33%
1 Month
+12.61%
+12.61%
3 Month
+15.36%
+15.36%
6 Month
+8.21%
+8.21%
1 Year
+24.73%
+24.73%

More News

Read More
Revolutionary Magnetic Therapy Could Speed Up Bipolar Treatment
Via PressReach
Exposures Product Safety
Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years
Via Benzinga
A Closer Look at AbbVie's Options Market Dynamics
Via Benzinga
AbbVie, Leidos, KKR And More On CNBC's 'Final Trades'
Via Benzinga
Large Cap Biopharma And Healthcare, A Port In A Storm
Via Talk Markets
Worried About a Market Correction? 2 High-Yield Dividend Stocks You Can Buy Now and Hold Forever.
Via The Motley Fool
8 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Evolus, A Medical Aesthetics Player, Becomes Profitable — Two Quarters Early
Via Investor's Business Daily
Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making?
Via InvestorPlace
7 Stocks Set for a Major Bull Run
Via InvestorPlace
3 Powerhouse Growth Stocks to Load Up On During This Bull Market Cycle
Via InvestorPlace
Bristol Myers, Johnson & Johnson, AbbVie, AstraZeneca Expect Minimal Impact From Upcoming Medicare Price Negotiations
Via Benzinga
AbbVie Analysts Lead the Stock Higher as Humira Worries Recede
Via MarketBeat
Topics Earnings Intellectual Property
Exposures Financial Intellectual Property
Pharma Stock Cuts Earnings Outlook: Still a Buying Opportunity
Via MarketBeat
3 High-Yield Dividend Stocks That Are Looking Super Hot
Via InvestorPlace
3 Dividend-Paying ETFs to Secure Your Passive Income Stream
Via InvestorPlace
Topics ETFs
Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)
From Alector, Inc.
Via GlobeNewswire
AbbVie Wins Analyst Confidence with Q2 Beat, Diverse Portfolio Fuels Long-Term Growth Expectations
Via Benzinga
Lockheed Martin To Rally Over 14%? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
Why AbbVie Stock Was Cruising Higher on Thursday
Via The Motley Fool
AbbVie (ABBV) Q2 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
ABBV Stock Earnings: AbbVie Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Stocks Rebound As US Economy Flexes Muscles, Small Caps Rally, Gold Falls: What's Driving Markets Thursday?
Via Benzinga
Topics Economy
Exposures Economy
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.